ABIVAX SA

Paris Stock Exchange ABVX.PA

ABIVAX SA Cash and Short-Term Investments for the year ending December 31, 2023: USD 288.07 M

ABIVAX SA Cash and Short-Term Investments is USD 288.07 M for the year ending December 31, 2023, a 899.03% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

ABIVAX SA Cash and Short-Term Investments for the year ending December 31, 2022 was USD 28.83 M, a -58.27% change year over year.
ABIVAX SA Cash and Short-Term Investments for the year ending December 31, 2021 was USD 69.10 M, a 93.04% change year over year.
ABIVAX SA Cash and Short-Term Investments for the year ending December 31, 2020 was USD 35.79 M, a 226.43% change year over year.
ABIVAX SA Cash and Short-Term Investments for the year ending December 31, 2019 was USD 10.97 M, a -26.31% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Paris Stock Exchange: ABVX.PA

ABIVAX SA

CEO	Mr. Marc M. P. de Garidel M.B.A.
IPO Date	June 26, 2015
Location	France
Headquarters	5, rue de la Baume
Employees	62
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Key trends

Past 5 years